(Q40124442)

17 September 2017

title

KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway (English)

1 reference

gastrointestinal stromal tumor

17 September 2017

main subject

1 reference

2

1 reference

17 September 2017

Bauer S

1

1 reference

17 September 2017

Demetri GD

series ordinal

3

1 reference

17 September 2017

Fletcher JA

series ordinal

4

1 reference

17 September 2017

language of work or name

English

0 references

publication date

4 June 2007

1 reference

17 September 2017

1 reference

17 September 2017

volume

26

1 reference

17 September 2017

issue

54

1 reference

17 September 2017

page(s)

7560-7568

1 reference

KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size

17 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210558

Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210558

7 January 2021

Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210558

7 January 2021

Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210558

7 January 2021

Extracellular KIT receptor mutants, commonly found in core binding factor AML, are constitutively active and respond to imatinib mesylate

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210558

7 January 2021

Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210558

7 January 2021

Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210558

7 January 2021

Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210558

7 January 2021

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210558

7 January 2021

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210558

7 January 2021

Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210558

7 January 2021

Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210558

7 January 2021

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210558

7 January 2021

Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210558

7 January 2021

Early signaling pathways activated by c-Kit in hematopoietic cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210558

7 January 2021

Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210558

7 January 2021

STAT3 activation is required for Asp(816) mutant c-Kit induced tumorigenicity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210558

7 January 2021

Oncogenic Kit signaling and therapeutic intervention in a mouse model of gastrointestinal stromal tumor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210558

7 January 2021

Overriding imatinib resistance with a novel ABL kinase inhibitor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210558

7 January 2021

STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210558

7 January 2021

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210558

7 January 2021

Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210558

7 January 2021

Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210558

7 January 2021

Identifiers

DOI

10.1038/SJ.ONC.1210558

1 reference

Dimensions Publication ID

17 September 2017

1050351441

0 references

Fatcat ID

release_eqyys6shkbeafomv6shdx5xwgy

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/eqyys6shkbeafomv6shdx5xwgy

24 November 2022

mapped directly with Wikidata item

1 reference